FMP

FMP

Enter

IOBT - IO Biotech, Inc.

Financial Summary of IO Biotech, Inc.(IOBT), IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer ther

photo-url-https://financialmodelingprep.com/image-stock/IOBT.png

IO Biotech, Inc.

IOBT

NASDAQ

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

1.48 USD

-0.01 (-0.676%)

About

ceo

Dr. Mai-Britt Zocca Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.iobiotech.com

exchange

NASDAQ

Description

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was i...

CIK

0001865494

ISIN

US4497781090

CUSIP

449778109

Address

Ole Maaløes Vej 3

Phone

45 70 70 29 80

Country

DK

Employee

68

IPO Date

Nov 5, 2021

Summary

CIK

0001865494

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

449778109

ISIN

US4497781090

Country

DK

Price

1.48

Beta

0.5

Volume Avg.

135.93k

Market Cap

97.5M

Shares

-

52-Week

0.816-2.64

DCF

3.23

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.75

P/B

-

Website

https://www.iobiotech.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest IOBT News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep